Effect of anti-IL-17 on airway responsiveness in asthma patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational longitudinal cohort study evaluates how monoclonal antibodies targeting interleukin 17 (anti-IL-17) influence airway hyperreactivity and resistance in adults with dermatological or rheumatological conditions. Participants planning to start anti-IL-17 treatment will undergo assessments of airway responsiveness using methacholine challenges and spirometry to measure changes in lung function. The study aims to determine if anti-IL-17 can effectively reduce airway hyperreactivity, particularly in patients with severe non-Type 2 asthma. This research is significant as it explores a novel treatment avenue for asthma patients who have not responded well to conventional therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients planning to start treatment with anti-IL-17 antibodies

Exclusion Criteria:

* Current pregnancy
* FEV1 \< 1.5L or less than 60% of predicted value expected.
* Previous anaphylactic shock or severe allergic reaction to medicine
* Uncontrolled hypertension
* Myocardial infarction or stroke within the last 3 months
* Known aortic aneurysm
* Recent eye surgery or risk of elevated intracranial pressure
* Treatment with systemic corticosteroids within 6 weeks

Where it's running

• Respiratory Research Unit Hvidovre Department of Respiratory Medicine, Copenhagen University Hospital
  Hvidovre, Capital Region, Denmark Recruiting

Study contacts

• Principal investigator: Jonas A Baekdal, MD — University hospital, Hvidovre
• Study coordinator: Jonas A Baekdal, MD
• Email: jonas.aggerholm.baekdal.02@regionh.dk
• Phone: +45 60134687

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Chronic Respiratory Disease Participant Engagement

  This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.

  Recruiting Richmond Pharmacology Limited · London · NCT07924462

• HB0056 in adults with moderate to severe asthma

  This study tests HB0056 versus a placebo to see if it helps adults with moderate to severe asthma reduce rescue inhaler use and improve symptoms.

  Recruiting at 2 sites Phase 1/2 Shanghai Huaota Biopharmaceutical Co., Ltd. · Beijing and 1 other locations · NCT07899996

• Tilrekimig (PF-07275315) for Severe Asthma: Aimed at Adults with Frequent Exacerbations

  This study tests whether tilrekimig helps people with severe asthma who have had multiple flare-ups in the past year, by comparing it to a placebo given every four weeks.

  Recruiting at 4 sites Phase 3 Pfizer · River Forest, Illinois and 11 other locations · NCT07869043

• Inhaled CHF10136 safety and pharmacokinetics in healthy adults and adults with asthma

  This first-in-human study tests inhaled CHF10136 to see if it is safe and well tolerated, how it behaves in the body, and how it affects adults with asthma compared with placebo.

  Recruiting Phase 1 Chiesi Farmaceutici S.p.A. · Leeds and 2 other locations · NCT07851623

• Biologics for Type 2 Inflammation in Asthma and COPD in Real World

  This real-world study tests whether six biologic drugs can reduce flare-ups and improve symptoms in adults with asthma or COPD treated in routine care in China.

  Recruiting Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07823842

• GSK5784283 vs placebo in uncontrolled asthma (PERSIST ASTHMA-2)

  A new medicine called GSK5784283 is being tested to see if it lowers asthma flare-ups better than a placebo in people with uncontrolled asthma.

  Recruiting at 7 sites Phase 3 GlaxoSmithKline · San Diego, California and 6 other locations · NCT07782996

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.